No Data
Alphamab Oncology To Publish Cancer Drug's Phase III Trial Results
Latest progress on the Phase III clinical trial of KN046 for the treatment of advanced squamous NSCLC by Conno Gene Pharmaceutical -B (09966).
Corning Jerritt Pharmaceuticals-B (09966) announced that it has released a notice regarding the Phase III clinical trial study of KN046...
HKEX News: Kunming Jerray Pharmaceuticals-B (09966) is currently down more than 5%, and the mid-year loss has expanded by 12% year-on-year. In May, it announced the failure of the KN046-303 clinical trial.
Kangning Jerry Pharmaceutical-B (09966) is now down more than 5%. As of the time of writing, it has dropped by 5.56% to HKD 2.38, with a turnover of HKD 4.2985 million.
Alphamab Oncology's Loss Widens in H1 as Other Gains Plunge; Shares Jump 7%
Alphamab Oncology Reports 2024 Interim Results and Business Highlights
Corning Jerry announces the mid-term performance for 2024 and recent business progress.
Suzhou, August 16, 2024 / PRNewswire / - Concord Medical Services Holdings Limited (stock code: 9966.HK) announced its 2024 interim results and recent business progress as of June 30, 2024. Financial Overview In the first half of 2024, the company's revenue was RMB 173.56 million, a year-on-year increase of 27.18%. Product revenue in the first half of 2024 was RMB 90.64 million, a year-on-year decrease of 22.54%. R&D expenditures in the first half of 2024 were RMB 194.53 million, basically flat year on year. In the first half of 2024,
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatioNo Data
